Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0OUTEE
ADC Name	Pertuzumab-Compound (XI)
Synonyms	Pertuzumab Compound (XI) Click to Show/Hide
Organization	Orum Therapeutics, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative
Drug-to-Antibody Ratio	1-2
Structure
	3D MOL	2D MOL
Antibody Name	Pertuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Undisclosed
Linker Name	Pertuzumab-Compound (XI) linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 45.2	%	HCC1569 cells	Breast ductal carcinoma
Tumor Growth Inhibition value (TGI)	≈ 71.4	%	HCC1569 cells	Breast ductal carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.20% (Day 22)	Positive HER2 expression (HER2 +++/++)
Method Description	Mice were orthotopically implanted with 1x10⁷ HCC1569 human breast cancer cells suspended in amixture of Matrigel and culture media in the inguinal fat pad. Following group allocation, mice were treated with a single 10 ml/kg lateral tail vein injection of a Pertuzumab-Compound (XI) conjugate at 3 mg/kg.
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.40% (Day 22)	Positive HER2 expression (HER2 +++/++)
Method Description	Mice were orthotopically implanted with 1x10⁷ HCC1569 human breast cancer cells suspended in amixture of Matrigel and culture media in the inguinal fat pad. Following group allocation, mice were treated with a single 10 ml/kg lateral tail vein injection of a Pertuzumab-Compound (XI) conjugate at 10 mg/kg.
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

References

Ref 1	Linkers for use in antibody drug conjugates; 2023-03-16.